ArticleMedicine2025
A case of psittacosis chlamydia pneumonia in patients with anti-infection drugs analysis and pharmaceutical care.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationalePsittacosis pneumonia, caused by Chlamydia psittaci, is an underdiagnosed zoonotic infection. This case aims to demonstrate the efficacy of azithromycin as an alternative therapy and highlight the value of clinical pharmacists in managing drug-resistant infections. PATIENT CONCERNS: A 56-year-old female poultry farmer presented with persistent high fever (38.5-39.0°C), chills, body aches, and fatigue for 2 weeks. Initial outpatient treatment with unspecified oral medication provided no relief. DIAGNOSES: Metagenomic next-generation sequencing of bronchoalveolar lavage fluid confirmed C psittaci and rhinovirus co-infection, explaining treatment failure with empirical piperacillin-tazobactam for presumed bacterial pneumonia.
interventionsAfter pathogen identification, intravenous azithromycin monotherapy (4.5 g total dose) was initiated. Clinical pharmacists collaborated on regimen design, monitored for QTc prolongation/electrolyte imbalances, and ensured safety during the 12-day course. OUTCOMES: Fever resolved within 48 hours; all symptoms improved by day 6. Follow-up computed tomography showed significant resolution of lung consolidation. The patient was discharged on day 11 with oral azithromycin continuation. LESSONS: Azithromycin is effective as second-line therapy for severe psittacosis when tetracyclines are inaccessible. Metagenomic next-generation sequencing enables rapid diagnosis of atypical pathogens, while pharmacist-led pharmaceutical care optimizes antimicrobial selection and safety monitoring, particularly for cardiotoxic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.